Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Risk Factors for Fluconazole-Resistant Candida glabrataBloodstream Infections

Risk Factors for Fluconazole-Resistant Candida glabrataBloodstream Infections ORIGINAL INVESTIGATION Risk Factors for Fluconazole-Resistant Candida glabrata Bloodstream Infections Ingi Lee, MD, MSCE; Neil O. Fishman, MD; Theoklis E. Zaoutis, MD, MSCE; Knashawn H. Morales, ScD; Mark G. Weiner, MD; Marie Synnestvedt, PhD; Irving Nachamkin, DrPH, MPH; Ebbing Lautenbach, MD, MPH, MSCE Background: Bloodstream infections (BSIs) caused by demographic data, comorbid conditions, and antimicro- Candida glabrata have increased substantially. Candida bial exposures. glabrata is often associated with resistance to flucona- zole therapy. However, to our knowledge, risk factors Results: We included 76 patients with fluconazole- for fluconazole-resistant C glabrata BSIs have not been resistant C glabrata BSIs, 68 patients with fluconazole- studied. susceptible C glabrata BSIs, and 512 control patients. Pre- vious fluconazole use (adjusted odds ratio [95% confidence Methods: A case-case-control study was conducted at interval], 2.3 [1.3-4.2]) and linezolid use (4.6 [2.2-9.3]) 3 hospitals from January 1, 2003, to May 31, 2007. The were independent risk factors for fluconazole-resistant 2 case groups included patients with fluconazole- C glabrata BSIs; previous cefepime use (2.2 [1.2-3.9]) and resistant C glabrata BSIs (minimum inhibitory concen- metronidazole use (2.0 [1.1-3.5]) were independent risk tration 16 µg/mL) and patients with fluconazole- factors for fluconazole-susceptible C glabrata BSIs. susceptible C glabrata BSIs http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Risk Factors for Fluconazole-Resistant Candida glabrataBloodstream Infections

Download PDF
5 pages

Loading next page...
 
/lp/american-medical-association/risk-factors-for-fluconazole-resistant-candida-glabratabloodstream-IyhjJsnj70

References (36)

Publisher
American Medical Association
Copyright
Copyright 2009 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinte.169.4.379
pmid
19237722
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL INVESTIGATION Risk Factors for Fluconazole-Resistant Candida glabrata Bloodstream Infections Ingi Lee, MD, MSCE; Neil O. Fishman, MD; Theoklis E. Zaoutis, MD, MSCE; Knashawn H. Morales, ScD; Mark G. Weiner, MD; Marie Synnestvedt, PhD; Irving Nachamkin, DrPH, MPH; Ebbing Lautenbach, MD, MPH, MSCE Background: Bloodstream infections (BSIs) caused by demographic data, comorbid conditions, and antimicro- Candida glabrata have increased substantially. Candida bial exposures. glabrata is often associated with resistance to flucona- zole therapy. However, to our knowledge, risk factors Results: We included 76 patients with fluconazole- for fluconazole-resistant C glabrata BSIs have not been resistant C glabrata BSIs, 68 patients with fluconazole- studied. susceptible C glabrata BSIs, and 512 control patients. Pre- vious fluconazole use (adjusted odds ratio [95% confidence Methods: A case-case-control study was conducted at interval], 2.3 [1.3-4.2]) and linezolid use (4.6 [2.2-9.3]) 3 hospitals from January 1, 2003, to May 31, 2007. The were independent risk factors for fluconazole-resistant 2 case groups included patients with fluconazole- C glabrata BSIs; previous cefepime use (2.2 [1.2-3.9]) and resistant C glabrata BSIs (minimum inhibitory concen- metronidazole use (2.0 [1.1-3.5]) were independent risk tration 16 µg/mL) and patients with fluconazole- factors for fluconazole-susceptible C glabrata BSIs. susceptible C glabrata BSIs

Journal

JAMA Internal Medicine – American Medical Association

Published: Feb 23, 2009

There are no references for this article.